Published : Jun-2020
No. of Pages : 35
1.1 List of Tables
1.2 List of Figures
2 Non-Alcoholic Steatohepatitis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Total Prevalence of NASH (%)
3.3.2 Diagnosed Prevalence of NASH (%)
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.4.4 Total Prevalent Cases of NASH
3.4.5 Diagnosed Prevalent Cases of NASH
3.4.6 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
3.5 Epidemiological Forecast for NASH (2019-2029)
3.5.1 Total Prevalent Cases of NASH
3.5.2 Diagnosed Prevalent Cases of NASH
3.5.3 Age-Specific Diagnosed Prevalent Cases of NASH
3.5.4 Sex-Specific Diagnosed Prevalent Cases of NASH
3.5.5 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Risk Factors and Comorbidities for NASH
Table 3: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: 7MM, Total Prevalent Cases of NASH, Both Sexes, 2019 and 2029
Figure 2: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, 2019 and 2029
Figure 3: 7MM, Total Prevalence of NASH (%), Both Sexes, All Ages, 2009?2029
Figure 4: 7MM, Diagnosed Prevalence of NASH (%), Both Sexes, All Ages, 2009?2029
Figure 5: 7MM, Sources Used for NASH Total Prevalence
Figure 6: 7MM, Sources Used for Obesity Prevalence
Figure 7: 7MM, Sources Used for the Diagnosed Prevalent Cases of NASH and Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
Figure 8: 7MM, Total Prevalent Cases of NASH, Both Sexes, All Ages, 2019
Figure 9: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, All Ages, 2019
Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of NASH, Both Sexes, 2019
Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of NASH, All Ages, 2019
Figure 12: 7MM, Diagnosed Prevalent Cases of NASH by Stage of Fibrosis, Both Sexes, All Ages, 2019
